Abstract
Objectives
To evaluate and compare the profile of expression of genes related to drug resistance in brain tumors and to analyze the impact of the increased expression of these genes on overall survival.
Methods
Eighty microdissected brain tumor samples from 79 patients were analyzed by RQ-PCR for the genes MDR1, MRP1, MRP3, LRP and BCRP. Protein expression was assessed by immunohistochemistry for MRP1 and LRP genes. Pediatric cases (0 to 20 years): 46 (17F:29M, median age 7.3 ± 5.9 years); adult tumors: 33 (17F:16M, median age 46.6 ± 14.5 years). Histological diagnoses: 21 astrocytomas I and II, 28 astrocytomas III and glioblastomas, 17 medulloblastomas, 8 ependymomas, and 6 oligodendrogliomas.
Results
glial tumors expressed higher MDR1 (P = 0.003) and BCRP (P = 0.03) levels than embryonic tumors. Low-grade astrocytomas expressed high MDR1 (P = 0.001), MRP3 (P = 0.01) and LRP (P = 0.02) levels. The MRP1 gene was preferentially expressed by medulloblastomas (P = 0.04) and ependymomas (P = 0.04); ependymomas also presented an increase of LRP (P = 0.02). The mRNA levels of MRP1 and LRP genes were associated to protein expression. The profile of gene expression of primary pilocytic astrocytomas of the hypothalamus and of the other locations was similar. Increased expression of resistance genes, separately or jointly, was not correlated with shorter overall survival in patients with medulloblastomas/PNET and malignant gliomas.
Conclusions
Drug resistance genes do not explain the higher sensitivity of gliomas of the hypothalamus/pituitary/optic pathways to chemotherapy. The increased expression of resistance genes had no impact on the overall survival of patients with medulloblastomas/PNET and high grade gliomas. High MDR1, MRP3 and LRP levels may be implicated in the primary resistance of pilocytic astrocytomas to chemotherapy.
Similar content being viewed by others
References
Potter R, Czech T, Diekmann K, Slavc I, Wimberger-Prayer D, Budka H (1998) Tumours of central nervous system. In: Voûte PA, Kalifa C, Barret A (eds) Cancer in children—clinical management. Oxford University Press, pp 172–192
Brown R (1999) Cytotoxic drug resistance mechanisms—methods in molecular medicine. In: C Brown (ed) Resistance mechanisms to drugs. Humana Press, New Jersey, pp 30–59
den Boer ML, Pieters R, Kasemier KM, Rottier MMA, Zwaan CM, Kaspers GJL, Janka-Schaub GE, Henze G, Creutzig U, Scheper RJ, Veerman AJP (1998) Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, p-glycoprotein expression, and drug resistance in childhood leukemia. Blood 91(6):2092–2098
Fujimaki SI, Tadao F, Harigae H (2002) Quantitative analysis od a MDR1 transcript for prediction of drug resistance in acute leukemia. Clin Chem 48:811–817
Leith C, Kopecky KJ, Chen IM, Eijdems L, Slovak ML, Mcconnel TS, Head DR, Weick J, Grever MR, Appelbaum FR, Willman C (1999) Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, e LRP in acute myeloid leukemia. A Southwest Oncology Group Study. Neoplasia 94(3):1086–1099
Rumjanek VM, Trindade GS, Wagner-Souza K, Meletti-DE Oliveira MC, Marques-Santos LF, Maia RC, Capella MAM (2001) Multidrug resistance in tumor cells: characterisation of the multidrug resistant cell line K562-Lucena. Na Acad Bras Ci 73(1):57–69
Sakaeda T, Nakamura T, Okumura K (2002) MDR1 genotype-related pharmacokinetics and pharmacodynamics. Biol Pharm Bull 25(11):1391–1400
Gottesman MM, Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:385–427
Glavinas H, Krajcsi P, Cserepes J, Sarkadi B (2004) The role of ABC transporters in drug resistance, metabolism and toxicity. Curr Drug Deliv 1(1):27–42
Higgins CF, Linton KJ (2004) The ATP switch model for ABC transporters. Nat Struct Mol Biol Oct 11(10):918–926
Szakàcs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5(3):219–234
Chugani DC, Rome LH, Kedersha NL (1993) Evidence that vault ribonucleoprotein particles localize to the nuclear pore complex. J Cell Sci 106(Pt 1):23–29
Packer RJ, Sutton LN, Elterman R, Lange B, Goldwein J, Nicholson HS, Mulne L, Boyett J, D’angio G, Wechsler-Jentzsch K (1994) Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neurosurg 81(5):690–698
Matsumoto T, Tani E, Kaba K, Kochi N, Shindo H, Yamamoto Y, Sakamoto H, Furuyama J (1990) Amplification and expression of a multidrug resistance gene in human glioma cell lines. J Neurosurg 72(1):96–101
Kondo S, Kondo Y, Hara H, Kaakaji R, Peterson Jw, Morimura T, Takeuchi J, Barnett GH (1996) mdm2 gene mediates the expression of mdr1 gene and P-glycoprotein in a human glioblastoma cell line. Br J Cancer 74(8):1263–1268
Chou PM, Barquin N, Gonzalez-Crussi F, Ridaura Sanz C, Tomita T, Reyes-Mugica M (1996) Ependymomas in children express the multidrug resistance gene: immunohistochemical and molecular biologic study. Pediatr Pathol Lab Med 16(4):551–561
Chou PM, Reyes-Mugica M, Barquin N, Yasuda T, Tan X, Tomita T (1995) Multidrug resistance gene expression in childhood medulloblastoma: correlation with clinical outcome and DNA ploidy in 29 patients. Pediatr Neurosurg 23(6):283–291
Ashmore SM, Thomas DG, Darling JL (1999) Does P-glycoprotein play a role in clinical resistance of malignant astrocytoma? Anticancer Drugs 10(10):861–872
von Bossanyi P, Diete S, Dietzmann K, Warich-Kirches M, Kirches E (1997) Immunohistochemical expression of P-glycoprotein and glutathione S-transferases in cerebral gliomas and response to chemotherapy. Acta Neuropathol (Berl) 94(6):605–611
Sawada T, Kato Y, Sakayori N, Takekawa Y, Kobayashi M (1999) Expression of the multidrug-resistance P-glycoprotein (Pgp, MDR-1) by endothelial cells of the neovasculature in central nervous system tumors. Brain Tumor Pathol 16(1):23–27
Demeule Shedid D, Beaulieu E, Del Maestro RF, Moghrabi A, Ghosn PB, Moumdjian R, Berthelet F, Beliveau R (2001) Expression of multidrug-resistance P-glycoprotein (MDR1) in human brain tumors. Int J Cancer 93(1):62–66
Calatozzolo C, Gelati M, Ciusani E, Sciacca FL, Pollo B, Cajola L, Marras C, Silvani A, Vitellaro-Zuccarello L, Croci D, Boiardi A, Salmaggi A (2005) Expression of drug resistance proteins Pgp, MRP1, MRP3, MRP5 and GST-pi in human glioma. J Neurooncol 74(2):113–121
Billson AL, Palmer JB, Walker DA, Lowe J (1994) Multidrug resistance gene (MDR 1) expression in neuro-axial tumours of children and young adults. Br J Neurosurg 8(5):585–591
Tanaka Y, Abe Y, Tsugu A, Takamiya Y, Akatsuka A, Tsuruo T, Yamazaki H, Ueyama Y, Sato O, Tamaoki N (1994) Ultrastructural localization of P-glycoprotein on capillary endothelial cells in human gliomas. Virchows Arch 425(2):133–138
Decleves X, Fajac A, Lehmann-Che J, Tardy M, Mercier C, Hurbain I, Laplanche JL, Bernaudin JF, Scherrmann JM (2002) Molecular and functional MDR1-Pgp and MRPs expression in human glioblastomas multiforme cell lines. Int J Cancer 98(2):173–180
Abe T, Mori T, Wakabayashi Y, Nakagawa M, Cole SP, Koike K, Kuwano M, Hori S (1998) Expression of multidrug resistance protein gene in patients with glioma after chemotherapy. J Neurooncol 40(1):11–18
Bronger H, Konig J, Kopplow K, Steiner HH, Ahmadi R, Herold-Mende C, Keppler D, Nies AT (2005) ABCC drug efflux pumps and organic anion uptake transporters in human gliomas and the blood-tumor barrier. Cancer Res 65(24):11419–11428
Aronica E, Gorter JA, Redeker S, Van Vliet EA, Ramkema M, Scheffer GL, Scheper RJ, Van Der Valk P, Leenstra S, Baayen JC, Spliet WG, Troost D (2005) Localization of breast cancer resistance protein (BCRP) in microvessel endothelium of human control and epileptic brain. Epilepsia 46(6):849–857
Vogelgesang S, Kunert-Keil C, Cascorbi I, Mosyagin I, Schroder E, Runge U, Jedlitschky G, Kroemer HK, Oertel J, Gaab MR, Pahnke J, Walker LC, Warzok RW (2004) Expression of multidrug transporters in dysembryoplastic neuroepithelial tumors causing intractable epilepsy. Clin Neuropathol 23(5):223–231
Andersson U, Malmer B, Bergenheim AT, Brannstrom T, Henriksson R (2004) Heterogeneity in the expression of markers for drug resistance in brain tumors. Clin Neuropathol 23:21–27
Berger W, Spiegl-Kreinecker S, Buchroithner J, Elbling L, Pirker C, Fischer J, Micksche M (2001) Overexpression of the human major vault protein in astrocytic brain tumor cells. Int J Cancer 94:377–382
Acknowledgements
We would like to thank Dr Eduardo Rego, Dr Lorena Figueiredo-Pontes and Aglair Garcia, from the Hematology Department, that kindly provided us the IH antibodies. We also thank Dr Roberto Silva Costa, Dr Luciano Neder, Dr Daniel Brandão and Ana Maria Anselmi Dorigan, from the Pathology Department, for performing and interpreting the IH assays.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Valera, E.T., Lucio-Eterovic, A.K.B., Neder, L. et al. Quantitative PCR analysis of the expression profile of genes related to multiple drug resistance in tumors of the central nervous system. J Neurooncol 85, 1–10 (2007). https://doi.org/10.1007/s11060-007-9382-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-007-9382-7